Cancer Immunotherapy: A Brief History, The Latest Development of Typical Subtypes and Therapy Combination

Shirong Tan

doi:10.54097/hset.v30i.4943

Authors

Shirong Tan

DOI:

https://doi.org/10.54097/hset.v30i.4943

Keywords:

Cancer Immunotherapy; History of Cancer Immunology; Monoclonal Antibodies; Cancer Vaccines; STAT3; Wnt/β-catenin Signaling Pathway.

Abstract

The leading cause of death in humans has long been considered cancer. People have developed a variety of cancer treatments as science has advanced. However, the side effects and flaws of the therapies are still intolerable for patients. Cancer immunotherapy, which potentially can give a long-lasting treatment with minimal toxicities, finally appeared to address the inadequacies. Cancer immunotherapy keeps up with the advancements in contemporary health. In recent years, there have been many updates on the many subtypes of cancer immunotherapy. A brief history of cancer immunotherapy and the most current developments are summarized in this paper. The assessment also emphasizes the newest investment trend in cancer immunotherapy and prospective drug combinations.

Downloads

Download data is not yet available.

References

Podlaha O, Riester M, De S, Michor F. Evolution of the cancer genome. Trends Genet. 2012; 28: 155-63.

Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009; 458: 719-24.

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331: 1565-70.

Seager RJ, Hajal C, Spill F, Kamm RD, Zaman MH. Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. Converg Sci Phys Oncol. 2017; 3.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-99.

Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2018; 14: 49.

Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019; 574: 45-56.

Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25: 267-96.

Swann JB, Smyth MJ. Immune surveillance of tumors. The Journal of clinical investigation. 2007; 117: 1137-46.

Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013; 494: 361-5.

Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nature reviews Immunology. 2008; 8: 958-69.

Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14: 1014-22.

Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005; 8: 369-80.

Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3: 999-1005.

Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20: 651-68.

Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022; 13: 868695.

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl: S185-S98.

Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. Journal of Cancer Metastasis and Treatment. 2017; 3.

The Basics of Cancer Immunotherapy.

Oelschlaeger TA. Bacteria as tumor therapeutics? Bioeng Bugs. 2010; 1: 146-7.

McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006; 26: 154-8.

Jerne NK. The Natural-Selection Theory of Antibody Formation. Proc Natl Acad Sci U S A. 1955; 41: 849-57.

Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957; 147: 258-67.

Decker WK, da Silva RF, Sanabria MH, Angelo LS, Guimaraes F, Burt BM, et al. Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front Immunol. 2017; 8: 829.

Miller JFAP, Mitchell GF, Weiss NS. Cellular Basis of the Immunological Defects in Thymectomized Mice. Nature. 1967; 214: 992-7.

Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973; 137: 1142-62.

Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975; 16: 230-9.

Pavletic ZS, Armitage JO. Bone Marrow Transplantation for Cancer--An Update. The Oncologist. 1996; 1: 159-68.

Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999; 26: 66-73.

Dobosz P, Dzieciatkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol. 2019; 10: 2965.

McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002; 62: 209-43.

McCormack PL. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. Drugs. 2013; 73: 1491-502.

Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies; 2020.

Markham A. Margetuximab: First Approval. Drugs. 2021; 81: 599-604.

Markham A. Naxitamab: First Approval. Drugs. 2021; 81: 291-6.

Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022; 29: 1335-44.

Markham A. Tisotumab Vedotin: First Approval. Drugs. 2021; 81: 2141-7.

Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12: 278-87.

Zhuang X, Wang Z, Fan J, Bai X, Xu Y, Chou JJ, et al. Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance. Nature Communications. 2022; 13: 4431.

Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. Int J Mol Sci. 2019; 20.

Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. OncoImmunology. 2016; 5: e1163462.

Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, et al. Prospects of IL-2 in Cancer Immunotherapy. Biomed Res Int. 2018; 2018: 9056173-.

Guo J, Xiao Y, Iyer R, Lu X, Lake M, Ladror U, et al. Empowering therapeutic antibodies with IFN-α for cancer immunotherapy. PloS one. 2019; 14: e0219829-e.

Donnelly RP, Young HA, Rosenberg AS. An overview of cytokines and cytokine antagonists as therapeutic agents. Ann N Y Acad Sci. 2009; 1182: 1-13.

Pires IS, Hammond PT, Irvine DJ. Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress. Adv Ther (Weinh). 2021; 4: 2100035.

Xue D, Hsu E, Fu Y-X, Peng H. Next-generation cytokines for cancer immunotherapy. Antib Ther. 2021; 4: 123-33.

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nature Communications. 2020; 11: 3801.

Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. European Journal of Immunology. 2017; 47: 765-79.

Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science. 1996; 271: 1734-6.

Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Science Advances. 6: eabd2712.

Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020; 200: 108-19.

Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis. The Journal of Immunology. 2011; 186: 5173.

Kandel S, Adhikary P, Li G, Cheng K. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy. Cancer Letters. 2021; 510: 67-78.

Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. Journal of Hematology & Oncology. 2021; 14: 45.

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. American journal of cancer research. 2020; 10: 727-42.

Brunet J-F, Denizot F, Luciani M-F, Roux-Dosseto M, Suzan M, Mattei M-G, et al. A new member of the immunoglobulin superfamily—CTLA-4. Nature. 1987; 328: 267-70.

Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013; 13: 5-.

Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology. 2016; 39.

Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. Journal of Hematology & Oncology. 2020; 13: 110.

Dankner M, Gray-Owen SD, Huang Y-H, Blumberg RS, Beauchemin N. CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology. 2017; 6: e1328336-e.

Fei L, Ren X, Yu H, Zhan Y. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds? Frontiers in Immunology. 2021; 12.

Ghanei Z, Mehri N, Jamshidizad A, Joupari MD, Shamsara M. Immunization against leukemia inhibitory factor and its receptor suppresses tumor formation of breast cancer initiating cells in BALB/c mouse. Scientific Reports. 2020; 10: 11465.

Jiang Z, Sun H, Yu J, Tian W, Song Y. Targeting CD47 for cancer immunotherapy. Journal of Hematology & Oncology. 2021; 14: 180.

Liu JKH. Anti-cancer vaccines - a one-hit wonder? Yale J Biol Med. 2014; 87: 481-9.

Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. The Journal of Infectious Diseases. 2021; 224: S367-S78.

Fritah H, Rovelli R, Chiang CL-L, Kandalaft LE. The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews. 2022; 106.

Maurer DM, Butterfield LH, Vujanovic L. Melanoma vaccines: clinical status and immune endpoints. Melanoma Res. 2019; 29: 109-18.

Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother. 2014; 10: 52-63.

Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. European Journal of Cancer. 2015; 51: 2321-9.

Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, et al. Phase II Randomized Study of CMB305 and Atezolizumab Compared with Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. Journal of Clinical Oncology. 2021; 40: 1291-300.

Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers. 2021; 13: 1383.

Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T. 2011; 36: 197-202.

Yang L, Li A, Lei Q, Zhang Y. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. Journal of hematology & oncology. 2019; 12: 125-.

Diaz-Cano SJ. Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. International journal of molecular sciences. 2012; 13: 1951-2011.

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Molecular Cancer. 2019; 18: 10.

Haseeb M, Pirzada RH, Ain QU, Choi S. Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics. Cells. 2019; 8: 1380.

Li X, Xiang Y, Li F, Yin C, Li B, Ke X. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. Frontiers in Immunology. 2019; 10.

Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. Journal of Hematology & Oncology. 2020; 13: 165.

Staal FJT, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nature Reviews Immunology. 2008; 8: 581-93.

Suryawanshi A, Hussein MS, Prasad PD, Manicassamy S. Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity. Frontiers in immunology. 2020; 11: 122-.

Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2019; 25: 3074-83.

Wang B, Tian T, Kalland K-H, Ke X, Qu Y. Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy. Trends in Pharmacological Sciences. 2018; 39: 648-58.

Darnell JE, Kerr lM, Stark GR. Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins. Science. 1994; 264: 1415-21.

Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in Cancer Immunotherapy. Molecular Cancer. 2020; 19: 145.

Dutta P, Sabri N, Li J, Li WX. Role of STAT3 in lung cancer. JAKSTAT. 2015; 3: e999503-e.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine. 2004; 10: 48-54.

Komai T, Inoue M, Okamura T, Morita K, Iwasaki Y, Sumitomo S, et al. Transforming Growth Factor-β and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals. Frontiers in immunology. 2018; 9: 1364-.

Garg B, Giri B, Modi S, Sethi V, Castro I, Umland O, et al. NFκ B in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12. Gastroenterology. 2018; 155: 880-91. e8.

Su Y-L, Banerjee S, White SV, Kortylewski M. STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity. International journal of molecular sciences. 2018; 19: 1803.

Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer. The Journal of Immunology. 2013; 190: 3783.

Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery. 2019; 18: 99-115.

Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, et al. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling. Cancer Research. 2016; 76: 4124-35.

Cui X, Jia H, Xin H, Zhang L, Chen S, Xia S, et al. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities. Frontiers in immunology. 2021; 12: 778978-.

Kaminskiy Y, Melenhorst JJ. STAT3 Role in T-Cell Memory Formation. International Journal of Molecular Sciences; 2022.